Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-14 (statnews.com)
A research transformation: An open model for innovation at Biogen |
Biogen isn't shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development
Read more
2025-02-25 (openpr.com)
Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis
Press release - HTF Market Intelligence Consulting Private Limited - Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis - published on openPR.com
Read more
2025-01-09 (mundorh.com.br)
Biogen expands its commitment to employee well-being through a sabbatical program -
Biogen initiative highlights the importance of rest and personal development, strengthening the culture of work-life balance
Read more![[RSNA 2024] Neurophet targets global expansion as Alzheimer's therapies boost demand for brain imaging analysis < Special < Article -](https://images.businessradar.com/articles/16e7531d-8548-4cc4-a8ac-30fd562113c1)
2024-12-06 (koreabiomed.com)
[RSNA 2024] Neurophet targets global expansion as Alzheimer's therapies boost demand for brain imaging analysis < Special < Article -
CHICAGO, Ill. -- By Lee Han-soo/Korea Biomedical correspondent -- Korean medical AI company Neurophet unveiled its enhanced brain imaging analysis portfolio at the Radiological Society of North America (RSNA) 2024, showcasing newly FDA-cleared multiple sclerosis (MS) detection capabilities alongside
Read more
2024-12-03 (reuters.com)
Biogen expects steady growth for Alzheimer's drug Leqembi in near term |
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday.
Read more
2024-12-03 (wkzo.com)
Biogen expects steady growth for Alzheimers drug Leqembi in near term Everything Kalamazoo 590 AM 1069 FM
(Reuters) - Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday. (Reporting by Mariam Sunny in...
Read more
2024-11-09 (smartkarma.com)
Biogen Inc.: Market Expansion & Commercial Execution Of New Launches Driving Our 'Buy' Rating!
Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic...
Read more
2024-10-24 (solarindustrymag.com)
Recurrent Energy Puts Texas Solar Project into Operation
Recurrent Energy’s 134 MW Liberty Solar project, located near Houston, has reached commercial operation. Customers for the project include Autodesk, Biogen, EMD Electronics and Wayfair. Liberty Solar additionally expands energy capacity for the Midcontinent Independent System Operator (MISO) market.
Read more
2024-10-15 (femtechinsider.com)
Talkiatry Partners with Biogen; Expands Virtual Postpartum Depression Care Services
Talkiatry, a provider of in-network psychiatric care, has announced the expansion of its services to include virtual postpartum depression (PPD) care. This new initiative aims to improve access to mental health support for women experiencing...
Read more